U.S. Entertainment Stock News

Hycroft Mining Holding (HYMC) just dropped a detailed update on its 2025 to 2026 exploration program in Nevada, with new high grade silver hits at Vortex and Brimstone that could reshape future mine plans. See our latest analysis for Hycroft Mining Holding. The market has taken notice, with Hycroft Mining Holding’s share price returning 155.42 percent over the past month and a huge 975.44 percent year to date. The one year total shareholder return of 1107.88 percent shows momentum has sharply...

Service Corporation International (SCI) is back in focus after fresh data underscored two years of disappointing funeral service volumes, weak free cash flow, and falling returns on capital, all of which pressure its ability to fund growth or support shareholder payouts. See our latest analysis for Service Corporation International. Despite these operational headwinds, SCI's share price has held at about $78.73, with a modest year to date share price return. Its five year total shareholder...

Olema Pharmaceuticals (OLMA) just earned a spot in the S&P Biotechnology Select Industry Index, a milestone that can quietly reshape its shareholder base as index funds and biotech-focused investors take a closer look. See our latest analysis for Olema Pharmaceuticals. That index inclusion caps a wild run for Olema, with the share price at $28.18 after a 30 day share price return of 21.62 percent and a 90 day surge of 220.59 percent. The 1 year total shareholder return of 347.30 percent hints...

In December 2025, PAR Technology Corporation launched Smart Passes, a wallet-native loyalty solution within its PAR Punchh platform that lets restaurant brands deliver real-time, app-free rewards and offers through Apple and Google Wallet on guests’ mobile phones. This move positions PAR to deepen its role in restaurant guest engagement by integrating loyalty directly into everyday mobile behavior, potentially enhancing the appeal and revenue opportunity of its broader cloud platform for...

Alnylam Pharmaceuticals (ALNY) just earned a spot in the NASDAQ 100, a move that can channel more passive money into the stock and highlights how far the RNAi pioneer has come with investors. See our latest analysis for Alnylam Pharmaceuticals. The NASDAQ 100 inclusion caps a strong run, with the share price up sharply year to date and a five year total shareholder return above 200 percent, as investors reward recent R and D progress and the 250 million dollar manufacturing expansion. If...

Atai Beckley (NasdaqGM:ATAI) just earned a spot in the NASDAQ Biotechnology Index, a move that often draws in fresh institutional money as index funds rebalance and passive strategies update their biotech exposure. See our latest analysis for Atai Beckley. The inclusion in the NASDAQ Biotechnology Index caps a volatile stretch, with a 30 day share price return of 13.16 percent but a 90 day share price return still down 23.35 percent. At the same time, the year to date share price return of...

In recent weeks, VICI Properties has faced analyst downgrades tied to concerns over tenant stability and a regional gaming lease with Caesars Entertainment, even as it moves to diversify by adding Clairvest as a tenant and acquiring the operations of MGM Northfield Park in Ohio, a deal expected to close in the first half of 2026. This combination of tenant risk questions and expansion into non-core gaming assets highlights how VICI’s evolving portfolio could reshape its risk profile and...

Structure Therapeutics (GPCR) has quietly turned heads after its stock climbed roughly 84% over the past month and more than doubled in the past 3 months, despite ongoing losses and zero reported revenue. See our latest analysis for Structure Therapeutics. That surge has come after a year of choppy trading, with the latest 1 day and 7 day share price returns in the red, even as the 30 day and year to date share price returns point to strong, building momentum from a base of clinical stage...

Frontier Group Holdings (ULCC) is back on investors radar after naming President James G. Dempsey as Interim CEO, stepping in for longtime chief Barry L. Biffle, who shifts to an advisory role. See our latest analysis for Frontier Group Holdings. The leadership shake up lands as the share price sits at $5.06, with a strong 1 month share price return of 33.51 percent but a much weaker 1 year total shareholder return of negative 28.93 percent. This suggests short term momentum is building even...

Zillow Group (ZG) has quietly drifted lower over the past 3 months, even as annual revenue and net income growth stay solidly positive. That disconnect is what makes the stock interesting now. See our latest analysis for Zillow Group. Over the past year, Zillow Group’s 1 year total shareholder return of negative 7.39 percent and 90 day share price return of negative 11.12 percent suggest momentum has cooled. However, its 3 year total shareholder return of 111.58 percent shows the longer term...

Earlier this week, Pharvaris reported positive top-line results from its pivotal RAPIDe-3 trial of deucrictibant for on-demand treatment of hereditary angioedema attacks, meeting the primary endpoint with significantly faster symptom relief versus placebo. The company also confirmed plans to begin filing marketing authorization applications for deucrictibant in the first half of 2026, signaling a transition from late-stage development toward potential commercialization in this rare disease...

BXP, Inc. recently declared a regular quarterly cash dividend of US$0.70 per share for the October–December 2025 period, payable on January 29, 2026, and also extended CEO Owen D. Thomas’s employment agreement through 2029 while approving a multi-year equity-based Outperformance Plan tied to long-term share performance. Together with recent asset recycling moves and a large pre-leased development in Washington, DC, these actions highlight BXP’s focus on leadership stability, capital...

In recent days, Disc Medicine has come under pressure as questions from an FDA official and media reports cast doubt on the efficacy and accelerated review pathway of its lead EPP candidate, bitopertin, while insider share sales added to investor unease. Despite this scrutiny, Disc and several covering analysts report that FDA interactions remain collaborative, with current inquiries framed as procedural clarifications rather than formal challenges to bitopertin’s clinical benefit. We’ll now...

Viavi Solutions (VIAV) is back in the spotlight after a cluster of growth signals, including an outperforming Inertial Labs acquisition, a new federal timing contract, and a quantum security partnership. See our latest analysis for Viavi Solutions. Those growth moves seem to be landing with investors, with the share price at $18.41 and a powerful 90 day share price return of 48.35 percent feeding into an 82.28 percent year to date share price gain and a 79.43 percent one year total...

In December 2025, DXC Technology launched AdvisoryX, a global advisory and consulting group that combines strategic, operational, and technology expertise to help enterprises close the gap between AI ambition and real-world execution. By pairing consulting-led engagements with an engineering backbone and integrated AI lifecycle solutions, DXC is positioning AdvisoryX as a way for companies to move beyond AI pilots and pressure-driven adoption toward governed, scalable deployments that can...

On December 19, 2025, Martin Marietta Materials, Inc. amended its US$800,000,000 five-year senior unsecured revolving credit facility, extending the maturity date of borrowings under the agreement to December 21, 2030. This extension strengthens the company’s access to committed bank liquidity, offering greater visibility over funding for future capital needs and operations. Next, we’ll explore how locking in this revolving credit facility through 2030 may influence Martin Marietta’s...

On 13 December 2025, SiriusPoint Ltd. (NYSE: SPNT) was added to the S&P Insurance Select Industry Index, marking its inclusion among a key group of publicly traded insurance companies. This index inclusion coincides with very strong analyst enthusiasm and positive earnings estimate trends, which together may broaden institutional awareness and trading interest in the stock. Now we’ll explore how SiriusPoint’s addition to the S&P Insurance Select Industry Index could influence its existing...

Diodes (DIOD) just widened its footprint in automotive semis, rolling out new DXTN/P 78Q and 80Q bipolar transistors aimed at power switching, better efficiency, and tighter thermal control in harsh environments. See our latest analysis for Diodes. The launch of these automotive grade transistors lands at an interesting moment, with Diodes showing a 13.03 percent 1 month share price return but still carrying a 1 year total shareholder return of negative 18.75 percent. This suggests early...

CareDx Inc. has disclosed a proposed settlement of shareholder derivative lawsuits in federal and Delaware courts and, in December 2025, secured preliminary court approval for a deal centered on corporate governance reforms, while also amending its bylaws to adopt a majority voting standard for uncontested director elections. The combination of governance-focused settlement terms, a shift to majority voting for directors, and a new US$8.27 million ESOP-related shelf registration signals a...

Lennox International (LII) is back in the spotlight after mixed third quarter results forced a cut to full year guidance, exposed demand and inventory pressures, and drew a securities law investigation from Levi and Korsinsky. See our latest analysis for Lennox International. The guidance cut and legal overhang help explain why, even at a latest share price of $495.48, Lennox has posted a weak year to date share price return. At the same time, its three year total shareholder return of 110.63...

Genpact (G) just expanded its executive bench, adding leaders in corporate development, next generation enterprises, and legal to push its GenpactNext strategy deeper into advanced, AI driven solutions and startup partnerships. See our latest analysis for Genpact. The new hires land at a moment when sentiment is already improving, with a 30 day share price return of 9.33 percent and a 90 day share price return of 18.12 percent, while the 1 year total shareholder return of 14.81 percent...

ICON (ICLR) has quietly bounced about 9% over the past month, even though the stock is still down sharply this year. That mix of recent momentum and longer term underperformance raises a clear valuation question. See our latest analysis for ICON. The recent 1 day share price return of 3.09 percent and 30 day share price return of 8.86 percent suggest sentiment is improving, even though the year to date share price return remains negative and longer term total shareholder returns are still...

Sanmina (SANM) just put a brighter spotlight on its Energy segment by unveiling plans for a Houston factory dedicated to transformers and switchgear for the US grid, backed by early customer commitments and a fresh design partnership with Koncar. See our latest analysis for Sanmina. The move lands on top of already strong momentum, with Sanmina’s share price delivering a roughly 30 percent 90 day return and a near doubling year to date, while longer term total shareholder returns remain even...

In recent months, General Motors has scaled back parts of its electric vehicle push, ending BrightDrop electric van production, trimming EV capacity, and retooling plants toward gas-powered models, while investing billions of US dollars in U.S. facilities to manage tariff exposure and bolster cash flow from its traditional lineup. Alongside this reset, GM is leaning on share buybacks that have reduced its share count by very large percentages since 2015, expanding higher-margin software and...